Bank of Montreal’s Akari Therapeutics AKTX Stock Holding History

Bank of Montreal’s Portfolio AKTX Stock Details AKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-19	Closed	-$38K	–	4651
2018 Q3	$38K	Sell	19 -19	-50%	-$30.7K	﹤0.01%	3494
2018 Q2	$59K	Hold	38	–	–	﹤0.01%	3347
2018 Q1	$55K	Hold	38	–	–	﹤0.01%	3197
2017 Q4	$130K	Buy	38 +13	+52%	+$50.1K	﹤0.01%	2891
2017 Q3	$123K	Buy	25 +16	+178%	+$60K	﹤0.01%	2898
2017 Q2	$32K	Buy	+9	New	+$71.2K	﹤0.01%	3368

Other funds holding AKTX

Hikari Power Tokyo, Japan $855M AUM 14.24% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return

Bank of Montreal's AKTX Position: Q4 2018 in Review

Bank of Montreal sold out of Akari Therapeutics (AKTX) in Q4 2018, closing a stake of 19 shares — an estimated $38K sold.

Bank of Montreal first reported a position in AKTX in Q2 2017 and held it in 6 quarters. The position peaked at $130K in Q4 2017. 7 funds tracked by Wall St. Rank hold AKTX as of Q4 2018.

Bank of Montreal reported no remaining Akari Therapeutics position as of Q4 2018 after selling out during the quarter.
Bank of Montreal sold 19 Akari Therapeutics shares in Q4 2018, an estimated $38K.
Bank of Montreal first reported a position in Akari Therapeutics in Q2 2017 and held it in 6 quarters.
Bank of Montreal's Akari Therapeutics position peaked at $130K in Q4 2017.
7 funds tracked by Wall St. Rank held Akari Therapeutics as of Q4 2018.

Based on Bank of Montreal's 13F filing for Q4 2018, filed 22 Jan 2019.